Provention Bio Inc. [NASDAQ: PRVB] slipped around -1.73 points on Friday, while shares priced at $8.00 at the close of the session, down -17.82%. The company report on April 9, 2021 that Provention Bio Provides Regulatory Update on Biologics License Application for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals.
– Conference call and webcast to be held at 5:00 p.m. Eastern Time -.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, announced that the Company received a notification on April 2, 2021 from the U.S. Food and Drug Administration (FDA), stating that, as part of its ongoing review of the Company’s Biologic License Application (BLA) for teplizumab for the delay or prevention of clinical type 1 diabetes, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The FDA stated in the correspondence that the notification does not reflect a final decision on the information under review.
Provention Bio Inc. stock is now -52.77% down from its year-to-date (YTD) trading value. PRVB Stock saw the intraday high of $8.44 and lowest of $6.36 per share. The company’s 52-week high price is 20.05, which means current price is +25.79% above from all time high which was touched on 01/12/21.
Compared to the average trading volume of 1.12M shares, PRVB reached a trading volume of 19439473 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Provention Bio Inc. [PRVB]?
SVB Leerink have made an estimate for Provention Bio Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on April 09, 2021. While these analysts kept the previous recommendation, RBC Capital Mkts dropped their target price from $27 to $25. The new note on the price target was released on April 09, 2021, representing the official price target for Provention Bio Inc. stock. Previously, the target price had yet another raise from $20 to $26, while H.C. Wainwright kept a Buy rating on PRVB stock.
The Average True Range (ATR) for Provention Bio Inc. is set at 1.00 The Price to Book ratio for the last quarter was 4.08, with the Price to Cash per share for the same quarter was set at 1.58.
How has PRVB stock performed recently?
Provention Bio Inc. [PRVB] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -27.50. With this latest performance, PRVB shares dropped by -35.64% in over the last four-week period, additionally sinking by -44.71% over the last 6 months – not to mention a drop of -7.51% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PRVB stock in for the last two-week period is set at 25.07, with the RSI for the last a single of trading hit 19.07, and the three-weeks RSI is set at 29.39 for Provention Bio Inc. [PRVB]. The present Moving Average for the last 50 days of trading for this stock 12.85, while it was recorded at 9.56 for the last single week of trading, and 13.79 for the last 200 days.
Provention Bio Inc. [PRVB]: Deeper insight into the fundamentals
Return on Total Capital for PRVB is now -102.76, given the latest momentum, and Return on Invested Capital for the company is -101.66. Return on Equity for this stock declined to -102.03, with Return on Assets sitting at -91.91. When it comes to the capital structure of this company, Provention Bio Inc. [PRVB] has a Total Debt to Total Equity ratio set at 0.71. Additionally, PRVB Total Debt to Total Capital is recorded at 0.70, with Total Debt to Total Assets ending up at 0.61. Long-Term Debt to Equity for the company is recorded at 0.64, with the Long-Term Debt to Total Capital now at 0.64.
Provention Bio Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.60 and a Current Ratio set at 7.60.
Earnings analysis for Provention Bio Inc. [PRVB]
With the latest financial reports released by the company, Provention Bio Inc. posted -0.26/share EPS, while the average EPS was predicted by analysts to be reported at -0.25/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -4.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PRVB.
Insider trade positions for Provention Bio Inc. [PRVB]
There are presently around $179 million, or 38.40% of PRVB stock, in the hands of institutional investors. The top three institutional holders of PRVB stocks are: PERCEPTIVE ADVISORS LLC with ownership of 4,224,389, which is approximately -0.969% of the company’s market cap and around 19.84% of the total institutional ownership; BLACKROCK INC., holding 3,925,489 shares of the stock with an approximate value of $31.4 million in PRVB stocks shares; and GILDER GAGNON HOWE & CO LLC, currently with $18.88 million in PRVB stock with ownership of nearly 9.681% of the company’s market capitalization.
Positions in Provention Bio Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 52 institutional holders increased their position in Provention Bio Inc. [NASDAQ:PRVB] by around 1,710,250 shares. Additionally, 46 investors decreased positions by around 1,614,295 shares, while 19 investors held positions by with 19,050,843 shares. The mentioned changes placed institutional holdings at 22,375,388 shares, according to the latest SEC report filing. PRVB stock had 18 new institutional investments in for a total of 285,974 shares, while 10 institutional investors sold positions of 738,496 shares during the same period.